GlycoVaxyn AG
LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedic
Basic Information
- Category: business
- Website: https://lmtbio.com/
Documented Facts
- Email: info@lmtbio.com (No linked source recorded for this statement.)
- Website: https://lmtbio.com/ (No linked source recorded for this statement.)
- Country: Switzerland (No linked source recorded for this statement.)
Evidence and Sources
- GlycoVaxyn AG — Official Site (official)
- GlycoVaxyn AG on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about GlycoVaxyn AG.
- Canonical profile: https://brandsource.ai/brands/glycovaxyn-ag
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/glycovaxyn-ag/json-ld
- Citation profile API: https://brandsource.ai/api/brands/glycovaxyn-ag/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (87/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedic
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.